Our experimental molecular studies indicate that the observed low expression of miR-22 in CTCL was due to constitutive repression of miR-22 transcription by aberrant Jak3/STAT signaling in malignant T cells. This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.